NCT05755750 is a Phase 3 clinical trial of Genipin in Superficial Digital Flexor Tendonitis, sponsored by University of Zurich.

Who is sponsoring NCT05755750?

NCT05755750 is sponsored by University of Zurich.

What drugs are being tested in NCT05755750?

Interventions in NCT05755750: Genipin.

What condition does NCT05755750 study?

NCT05755750 studies Superficial Digital Flexor Tendonitis.

Is NCT05755750 still recruiting?

NCT05755750 is currently completed. Last updated 6 March 2023.

Last reviewed 2023-03-06 · How we verify

NCT05755750

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intratendinous Genipin Injection in Horses With Tendon Injuries

Completed Phase 3 Last updated 6 March 2023

What this trial tests

Phase 3 trial testing Genipin in Superficial Digital Flexor Tendonitis in 74 participants. Completed in 4 January 2023.

Timeline

28 June 2016

Primary endpoint
4 January 2023

4 January 2023

Quick facts

Lead sponsor	University of Zurich
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	74
Start date	28 June 2016
Primary completion	4 January 2023
Estimated completion	4 January 2023
Sites	1 location across Switzerland

Drugs / interventions tested

Genipin — full drug profile →

Conditions studied

Superficial Digital Flexor Tendonitis — all drugs for Superficial Digital Flexor Tendonitis →

Sponsor

University of Zurich

Who can join

Eligibility, any sex, with Superficial Digital Flexor Tendonitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our study is the first to use genipin, a naturally occurring collagen cross-linking agent, as a therapeutic agent to treat superficial digital flexor tendon (SDFT) injuries in horses. The promising approach of intratendinous genipin injection and tendon mechanical enhancement could be a viable alternative to current therapies for SDFT injuries.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting mitochondrial quality control: new therapeutic strategies for major diseases.
Hong WL, Huang H, Zeng X, Duan CY. · · 2024 · cited 38× · PMID 39164792 · DOI 10.1186/s40779-024-00556-1

Verify or expand the search:

Other University of Zurich trials

Trials by the same sponsor.

NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05755750 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Zurich
Last refreshed: 6 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05755750.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing